Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
- Published Date : June 2, 2026
- Updated On : February 9, 2026
- Pages : 150
MOG Antibody-associated Disease Market Outlook and Forecast
Thelansis’s “Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential MOG Antibody-associated Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
MOG Antibody-associated Disease Overview
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune inflammatory demyelinating disorder of the central nervous system associated with pathogenic MOG-IgG. The disease commonly presents with optic neuritis, transverse myelitis, or acute disseminated encephalomyelitis and may also involve the brainstem, cerebellum, or cerebral cortex. MOGAD can follow either a monophasic or relapsing course, with recurrent attacks contributing to persistent visual or neurological disability in some patients. Acute management generally relies on high-dose corticosteroids, with intravenous immunoglobulin or plasma exchange used in severe or incompletely responsive attacks, while relapse prevention may involve IVIG, rituximab, mycophenolate, azathioprine, corticosteroids, or IL-6-directed therapy. However, long-term treatment remains largely empiric, with limited comparative evidence and no approved MOGAD-specific disease-modifying therapy as of September 2026. The field is now moving toward targeted immunotherapy. In the Phase 3 METEOROID trial, satralizumab reduced the risk of relapse by 68% versus placebo, and the program received FDA Priority Review in September 2026. Meanwhile, the FcRn antagonist rozanolixizumab remains in a Phase 3 pivotal study, aiming to reduce pathogenic IgG through accelerated antibody clearance. Antigen-specific tolerance strategies remain an earlier research frontier, underscoring continued opportunity for more precise and durable immune-directed therapies.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
MOG Antibody-associated Disease Market Outlook and Forecast
Thelansis’s “Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential MOG Antibody-associated Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
MOG Antibody-associated Disease Overview
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune inflammatory demyelinating disorder of the central nervous system associated with pathogenic MOG-IgG. The disease commonly presents with optic neuritis, transverse myelitis, or acute disseminated encephalomyelitis and may also involve the brainstem, cerebellum, or cerebral cortex. MOGAD can follow either a monophasic or relapsing course, with recurrent attacks contributing to persistent visual or neurological disability in some patients. Acute management generally relies on high-dose corticosteroids, with intravenous immunoglobulin or plasma exchange used in severe or incompletely responsive attacks, while relapse prevention may involve IVIG, rituximab, mycophenolate, azathioprine, corticosteroids, or IL-6-directed therapy. However, long-term treatment remains largely empiric, with limited comparative evidence and no approved MOGAD-specific disease-modifying therapy as of September 2026. The field is now moving toward targeted immunotherapy. In the Phase 3 METEOROID trial, satralizumab reduced the risk of relapse by 68% versus placebo, and the program received FDA Priority Review in September 2026. Meanwhile, the FcRn antagonist rozanolixizumab remains in a Phase 3 pivotal study, aiming to reduce pathogenic IgG through accelerated antibody clearance. Antigen-specific tolerance strategies remain an earlier research frontier, underscoring continued opportunity for more precise and durable immune-directed therapies.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)